Cargando…
Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance
The global emergence of antibacterial resistance among common and atypical respiratory pathogens in the last decade necessitates the strategic application of antibacterial agents. The use of bactericidal rather than bacteriostatic agents as first-line therapy is recommended because the eradication o...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873758/ https://www.ncbi.nlm.nih.gov/pubmed/12533275 http://dx.doi.org/10.3201/eid0901.020172 |
_version_ | 1782181392245850112 |
---|---|
author | Stratton, Charles W. |
author_facet | Stratton, Charles W. |
author_sort | Stratton, Charles W. |
collection | PubMed |
description | The global emergence of antibacterial resistance among common and atypical respiratory pathogens in the last decade necessitates the strategic application of antibacterial agents. The use of bactericidal rather than bacteriostatic agents as first-line therapy is recommended because the eradication of microorganisms serves to curtail, although not avoid, the development of bacterial resistance. Bactericidal activity is achieved with specific classes of antimicrobial agents as well as by combination therapy. Newer classes of antibacterial agents, such as the fluoroquinolones and certain members of the macrolide/lincosamine/streptogramin class have increased bactericidal activity compared with traditional agents. More recently, the ketolides (novel, semisynthetic, erythromycin-A derivatives) have demonstrated potent bactericidal activity against key respiratory pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Moraxella catarrhalis. Moreover, the ketolides are associated with a low potential for inducing resistance, making them promising first-line agents for respiratory tract infections. |
format | Text |
id | pubmed-2873758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-28737582010-05-24 Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance Stratton, Charles W. Emerg Infect Dis Perspective The global emergence of antibacterial resistance among common and atypical respiratory pathogens in the last decade necessitates the strategic application of antibacterial agents. The use of bactericidal rather than bacteriostatic agents as first-line therapy is recommended because the eradication of microorganisms serves to curtail, although not avoid, the development of bacterial resistance. Bactericidal activity is achieved with specific classes of antimicrobial agents as well as by combination therapy. Newer classes of antibacterial agents, such as the fluoroquinolones and certain members of the macrolide/lincosamine/streptogramin class have increased bactericidal activity compared with traditional agents. More recently, the ketolides (novel, semisynthetic, erythromycin-A derivatives) have demonstrated potent bactericidal activity against key respiratory pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Moraxella catarrhalis. Moreover, the ketolides are associated with a low potential for inducing resistance, making them promising first-line agents for respiratory tract infections. Centers for Disease Control and Prevention 2003-01 /pmc/articles/PMC2873758/ /pubmed/12533275 http://dx.doi.org/10.3201/eid0901.020172 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Perspective Stratton, Charles W. Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance |
title | Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance |
title_full | Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance |
title_fullStr | Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance |
title_full_unstemmed | Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance |
title_short | Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance |
title_sort | dead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistance |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873758/ https://www.ncbi.nlm.nih.gov/pubmed/12533275 http://dx.doi.org/10.3201/eid0901.020172 |
work_keys_str_mv | AT strattoncharlesw deadbugsdontmutatesusceptibilityissuesintheemergenceofbacterialresistance |